Wellington Management Group LLP Purchases 26,709 Shares of Krystal Biotech, Inc. $KRYS

Wellington Management Group LLP increased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 261.2% during the second quarter, Holdings Channel.com reports. The institutional investor owned 36,936 shares of the company’s stock after purchasing an additional 26,709 shares during the period. Wellington Management Group LLP’s holdings in Krystal Biotech were worth $13,728,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Silvant Capital Management LLC purchased a new position in Krystal Biotech during the 2nd quarter valued at approximately $30,000. Western Wealth Management LLC bought a new stake in Krystal Biotech in the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC purchased a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $34,000. Danske Bank A S purchased a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $35,000. Finally, UMB Bank n.a. boosted its position in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

KRYS opened at $358.24 on Tuesday. The stock’s 50 day moving average price is $349.42 and its 200-day moving average price is $308.09. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54. The stock has a market cap of $10.60 billion, a price-to-earnings ratio of 44.89 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The firm had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. As a group, analysts predict that Krystal Biotech, Inc. will post 7.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price target on the stock. Citigroup increased their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. TD Cowen lifted their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Finally, Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $365.40.

Insiders Place Their Bets

In other news, EVP John Thomas sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 51,000 shares of company stock worth $17,558,270 over the last quarter. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.